Progress Study
IBSA Group and Inception Fertility want to make the embryo transfer process a little simpler for patients—and we need your help to make that progress.
IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.
A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.
IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.
A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.
Key Participant Requirements
The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:
- Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS)
- Have a normal pap smear
- Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease
For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116
Key Participant Requirements
The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:
- Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS)
- Have a normal pap smear
- Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease
For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116
Attend scheduled clinic visits.
Receive study medications to self-administer as instructed by the clinic staff.
Attend scheduled clinic visits.
Have blood drawn to evaluate hormone levels.
Receive study medications to self-administer as instructed by the clinic staff.
As part of the study, participants will receive
a credit toward their IVF/FET cycle cost, PGT-A testing via Igenomix, progesterone and Ovidrel, a medication that induces ovulation.
Sign up
©2023 Inception Fertility, Inc. All rights reserved.